Extended Insulin Zinc Suspension
If you find any inaccurate information, please let us know by providing your feedback here

Tóm tắt nội dung
This article is compiled based on the United States Pharmacopeia (USP) – 2025 Edition
Issued and maintained by the United States Pharmacopeial Convention (USP)
1 DEFINITION
Extended Insulin Zinc Suspension is a sterile suspension of Insulin in buffered Water for Injection, modified by the addition of a suitable zinc salt in a manner such that the solid phase of the suspension is predominantly crystalline. Its potency, based on the sum of its insulin and desamido insulin components, is NLT 95.0% and NMT 105.0% of the potency stated on the label, expressed in USP Insulin Units/mL.
2 IDENTIFICATION
Change to read:
A. The retention time of the insulin pork (RB 1-May-2019) peak of Sample solution A or Sample solution B corresponds to that of (RB 1-May-2019) the Identification solution, as obtained in the Assay and no other signi cant peaks are observed. (RB 1-May-2019) [Note—It may be necessary to inject a mixture of Sample solution and Identification solution.]
3 ASSAY
Change to read:
3.1 Procedure
Solution A: Dissolve 28.4 g of anhydrous sodium sulfate in 1000 mL of water. Pipet 2.7 mL of phosphoric acid into the solution, and adjust with ethanolamine to a pH of 2.3, if necessary.
Mobile phase: Acetonitrile and Solution A (26:74). [Note—The acetonitrile is warmed to NLT 20° to avoid precipitation.]
System suitability solution: 1.5 mg/mL of (RB 1-May-2019) insulin pork in 0.01 N hydrochloric acid. (RB 1-May-2019) Allow to stand at room temperature for NLT 3 days to obtain a solution containing NLT 5% of A-21 desamido insulin.
Identification solution: (RB 1-May-2019) 0.6 mg/mL of USP Insulin Pork RS in 0.01 N hydrochloric acid. [Note—The Identification solution may
be stored at room temperature for up to 12 h or in a refrigerator for up to 48 h.]
Standard solution: 1.5 mg/mL of (RB 1-May-2019) USP Insulin Pork RS in 0.01 N hydrochloric acid (RB 1-May-2019)
Sample solution A (for Suspension labeled as containing 40 USP Insulin Units/mL): Add 2.5 μL of 9.6 N hydrochloric acid for each mL of an accurately measured volume of Suspension. Allow the suspension to clarify, and mix.
Sample solution B (for Suspension labeled as containing 100 USP Insulin Units/mL): Add 2.5 μL of 9.6 N hydrochloric acid for each mL of an accurately measured volume of Suspension. Allow the suspension to clarify, and mix. [Note—Pooling several package units may be necessary to obtain sufficient volume of the sample.] Pipet 2 mL of this solution into a 5-mL volumetric flask, dilute with 0.01 N hydrochloric acid to volume, and mix.
3.2 Chromatographic system
(See Chromatography 〈621〉, System Suitability.)
Mode: LC
Detector: UV 214 nm
Column: 4.6-mm × 15-cm; packing L1
Column temperature: 40°
Flow rate: 1 mL/min
Injection volume: 20 μL
3.3 System suitability
Samples: System suitability solution and Standard solution
3.4 Suitability requirements
Resolution: NLT 2.0 between insulin and A-21 desamido insulin, System suitability solution
Tailing factor: NMT 1.8 for the insulin peak, System suitability solution
Relative standard deviation: NMT 1.6%, Standard solution
3.5 Analysis
Samples: Identification solution, Standard solution, and either Sample solution A or Sample solution B
Measure the peak responses for insulin and A-21 desamido insulin using the chromatogram of the Identification solution to identify the insulin peaks. (RB 1-May-2019) Calculate the potency, in USP Insulin Units/mL, of the portion of Suspension taken:
Result = (ΣrU /ΣrS ) × C × D
ΣrU = sum of the peak responses of insulin and A-21 desamido insulin from the Sample solution
ΣrS = sum of the peak responses of insulin and A-21 desamido insulin from the Standard solution
C = concentration of (RB 1-May-2019) USP Insulin Pork RS in the Standard solution (USP Insulin Units/mL)
D = dilution factor used to prepare the Sample solution
Acceptance criteria: 95.0%–105.0% of the potency stated on the label, expressed in USP Insulin Units/mL
4 OTHER COMPONENTS
Zinc Determination 〈591〉: 0.12–0.25 mg for every 100 USP Insulin Units
Zinc in the Supernatant
Analysis: Centrifuge a portion of Suspension sufficient for the test and determine the zinc content of the clear supernatant as directed in Zinc Determination 〈591〉.
Acceptance criteria: Concentration of zinc (mg/mL) is 20%–65% of the zinc concentration of the Suspension.
5 PRODUCT-RELATED SUBSTANCES AND IMPURITIES
Physicochemical Analytical Procedures for Insulins 〈121.1〉, Limit of High Molecular Weight Proteins: Proceed as directed in Limit of High Molecular Weight Proteins, except prepare the following Sample solution. It meets the requirements.
Sample solution: Quantitatively add 4 μL of 6 N hydrochloric acid to each mL of an accurately measured volume of Suspension, and mix.
Acceptance criteria: NMT 1.5%
6 SPECIFIC TESTS
Insulin Not Extracted by Buffered Acetone Solution
Sample solution: Centrifuge a quantity of Suspension representing 1000 USP Insulin Units, and discard the supernatant. Suspend the residue in 8.4 mL of water, quickly add 16.6 mL of buffered acetone TS, shake or stir vigorously, and centrifuge within 3 min after the addition of the buffered acetone TS. Discard the supernatant, repeat the treatment with water and buffered acetone TS, centrifuge, and discard the supernatant. Dissolve the crystalline residue in 5 mL of dilute hydrochloric acid (1 in 100), transfer to a 25-mL flask, and dilute with water to volume.
Analysis: Use an appropriate method to determine the insulin concentration.
Acceptance criteria: The insulin concentration is NLT 90% of the insulin content of an equal amount of the Suspension.
Insulin in the Supernatant
Sample solution: Centrifuge 10 mL of the Suspension at 1500 × g for 10 min. Use the supernatant.
Analysis: Determine the insulin content of the Sample solution by a suitable method.
Acceptance criteria: NMT 1.0 USP Insulin Unit/mL
pH 〈791〉: 7.0–7.8
Bacterial Endotoxins Test 〈85〉: NMT 80 USP Endotoxin Units/100 USP Insulin Units
Sterility Tests 〈71〉, Test for Sterility of the Product to Be Examined, Membrane Filtration: Meets the requirements when tested as directed, and the Suspension being filtered immediately after it has been put into solution using a validated suitable solvent
7 ADDITIONAL REQUIREMENTS
Packaging and Storage: Preserve in the unopened, multiple-dose container provided by the manufacturer. Do not repackage. Store in a refrigerator, protect from sunlight, and avoid freezing.
Change to read:
Labeling: Label it (RB 1-May-2019) as porcine (RB 1-May-2019) . If the Extended Insulin Zinc Suspension is made from insulin that is purified, label it as such. The container label states that the Suspension is to be shaken carefully before use. Label it to state that it is to be stored in a refrigerator and that freezing is to be avoided. The label states the potency in USP Insulin Units/mL.
Change to read:
USP Reference Standards 〈11〉 (RB 1-May-2019)
USP Insulin Pork RS

